Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Enochian BioSciences Stock Skyrocketed Today

By Joe Tenebruso - Jun 14, 2021 at 3:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's experimental treatment for HIV could be a game changer.

What happened

Shares of Enochian BioSciences (ENOB 0.17%) soared on Monday after the biopharmaceutical company said the Food and Drug Administration (FDA) accepted its pre-investigational new drug request for a "potential functional cure" of HIV. 

As of 2:45 p.m. EDT, the biotech stock's price was up more than 100%.

So what

Enochian BioSciences said its cellular therapy could potentially allow people with HIV to stop antiviral treatment for long periods. Its request to the FDA was based on the results of a 54-year-old man who was unable to suppress the virus with antiviral therapy. A treatment of Natural Killer (NK) and Gamma Delta T-cells (GDT) collected from another person subsequently allowed the patient to achieve viral control for 255 days -- without the use of antiviral drugs.

A person is pointing to an upwardly sloping line.

Shares of Enochian BioSciences surged on Monday. Image source: Getty Images.

Enochian BioSciences believes Gamma Delta T-cells -- a small subset of immune cells that can be infected with HIV -- could help to control the virus. The biotech has an exclusive license for this proprietary technology.

"It is important to explore any potential for persons with HIV to safely stop antiviral drugs and control the virus," Dr. Peter Piot, the Director of the London School of Hygiene and Tropical Medicine, said in a press release. "Although the results so far are preliminary and in one person, if the NK-GDT therapy is proven to be effective in others, it could offer hope to many who experience significant side effects from, or have grown tired of, daily antiviral medication."

Now what

Enochian BioSciences hopes to evaluate the approach in more people, including those with HIV who have suppressed the virus with antiviral treatment. The company expects to receive written comments from the FDA this fall.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Enochian Biosciences, Inc. Stock Quote
Enochian Biosciences, Inc.
$2.45 (0.17%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.